Latest Breaking News On - Disease analysis set - Page 1 : comparemela.com

Immunic Inc (IMUX) Reports Positive Results from Phase 1b Trial of IMU-856

Immunic Inc (IMUX) Reports Positive Results from Phase 1b Trial of IMU-856
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealandAndreas muehlerPaula schwartzJessica breuDaniel vittEdna kaplanExchange commissionRx communications groupImmunic incWall streetCeliac disease symptom diaryChief executive officerChief medical officerTwo sample testDisease analysis set

EQS-News: Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders 04.05.2023 / 12:30 CET/CEST The issuer is solely responsib.

United statesNew zealandJessica breuEdna kaplanDaniel vittPaula schwartzAndreas muehlerGut healthExchange commissionDistribution servicesImmunic incRx communications groupReports positive results from phaseClinical trialCeliac diseaseProviding clinical proof of concept

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

United statesNew zealandDaniel vittEdna kaplanJessica breuPaula schwartzAndreas muehlerGut healthImmunic incRx communications groupExchange commissionPositive effectsDemonstrated overFour key dimensionsCeliac disease pathophysiologyGut architecture

EQS-News: Immunic, Inc : Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic

United statesNew zealandEdna kaplanDaniel vittJessica breuAndreas muehlerPaula schwartzGut healthDistribution servicesRx communications groupExchange commissionImmunic incReports positive results from phaseClinical trialCeliac diseaseProviding clinical proof of concept